|
1.
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2.
|
Bhoo-Pathy N, Yip CH, Hartman M, et al:
Breast cancer research in Asia: adopt or adapt Western knowledge?
Eur J Cancer. 49:703–709. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Longley DB and Johnston PG: Molecular
mechanisms of drug resistance. J Pathol. 205:275–292. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Baguley BC: Multiple drug resistance
mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Olsen EA: The pharmacology of
methotrexate. J Am Acad Dermatol. 25:306–318. 1991. View Article : Google Scholar
|
|
6.
|
Assaraf YG: Molecular basis of antifolate
resistance. Cancer Metastasis Rev. 26:153–181. 2007. View Article : Google Scholar
|
|
7.
|
de Almagro MC, Selga E, Thibaut R, Porte
C, Noe V and Ciudad CJ: UDP-glucuronosyltransferase 1A6
overexpression in breast cancer cells resistant to methotrexate.
Biochem Pharmacol. 81:60–70. 2011.PubMed/NCBI
|
|
8.
|
Selga E, Morales C, Noe V, Peinado MA and
Ciudad CJ: Role of caveolin 1, E-cadherin, Enolase 2 and PKCalpha
on resistance to methotrexate in human HT29 colon cancer cells. BMC
Med Genomics. 1:352008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Mencia N, Selga E, Noé V and Ciudad CJ:
Underexpression of miR-224 in methotrexate resistant human colon
cancer cells. Biochem Pharmacol. 82:1572–1582. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Mencia N, Selga E, Rico I, et al:
Overexpression of S100A4 in human cancer cell lines resistant to
methotrexate. BMC Cancer. 10:2502010. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Subramanian A and Miller DM: Structural
analysis of alpha-enolase. Mapping the functional domains involved
in down-regulation of the c-myc protooncogene. J Biol Chem.
275:5958–5965. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Takashima M, Kuramitsu Y, Yokoyama Y, et
al: Overexpression of alpha enolase in hepatitis C virus-related
hepatocellular carcinoma: association with tumor progression as
determined by proteomic analysis. Proteomics. 5:1686–1692. 2005.
View Article : Google Scholar
|
|
13.
|
Chang GC, Liu KJ, Hsieh CL, et al:
Identification of alpha-enolase as an autoantigen in lung cancer:
its overexpression is associated with clinical outcomes. Clin
Cancer Res. 12:5746–5754. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Tsai ST, Chien IH, Shen WH, et al: ENO1, a
potential prognostic head and neck cancer marker, promotes
transformation partly via chemokine CCL20 induction. Eur J Cancer.
46:1712–1723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Tu SH, Chang CC, Chen CS, et al: Increased
expression of enolase alpha in human breast cancer confers
tamoxifen resistance in human breast cancer cells. Breast Cancer
Res Treat. 121:539–553. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Chuthapisith S, Layfield R, Kerr ID,
Hughes C and Eremin O: Proteomic profiling of MCF-7 breast cancer
cells with chemoresistance to different types of anti-cancer drugs.
Int J Oncol. 30:1545–1551. 2007.PubMed/NCBI
|
|
17.
|
Mizukami Y, Iwamatsu A, Aki T, et al:
ERK1/2 regulates intracellular ATP levels through alpha-enolase
expression in cardiomyocytes exposed to ischemic hypoxia and
reoxygenation. J Biol Chem. 279:50120–50131. 2004. View Article : Google Scholar
|
|
18.
|
de Sousa Abreu R, Penalva LO, Marcotte EM
and Vogel C: Global signatures of protein and mRNA expression
levels. Mol Biosyst. 5:1512–1526. 2009.PubMed/NCBI
|
|
19.
|
Ivaska J, Pallari HM, Nevo J and Eriksson
JE: Novel functions of vimentin in cell adhesion, migration, and
signaling. Exp Cell Res. 313:2050–2062. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Singh S, Sadacharan S, Su S, Belldegrun A,
Persad S and Singh G: Overexpression of vimentin: role in the
invasive phenotype in an androgen-independent model of prostate
cancer. Cancer Res. 63:2306–2311. 2003.PubMed/NCBI
|
|
21.
|
Karihtala P, Auvinen P, Kauppila S,
Haapasaari KM, Jukkola-Vuorinen A and Soini Y: Vimentin, zeb1 and
Sip1 are up-regulated in triple-negative and basal-like breast
cancers: association with an aggressive tumour phenotype. Breast
Cancer Res Treat. 138:81–90. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Tseng YH, Chang KW, Yang CC, et al:
Association between areca-stimulated vimentin expression and the
progression of head and neck cancers. Head Neck. 34:245–253. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Kim JJ, Yin B, Christudass CS, et al:
Acquisition of paclitaxel resistance is associated with a more
aggressive and invasive phenotype in prostate cancer. J Cell
Biochem. 114:1286–1293. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Sun S, Wong TS, Zhang XQ, et al: Protein
alterations associated with temozolomide resistance in subclones of
human glioblastoma cell lines. J Neurooncol. 107:89–100. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Liu H, Zhang HW, Sun XF, et al:
Tamoxifen-resistant breast cancer cells possess cancer stem-like
cell properties. Chin Med J (Engl). 126:3030–3034. 2013.PubMed/NCBI
|
|
26.
|
Krecic AM and Swanson MS: hnRNP complexes:
composition, structure, and function. Curr Opin Cell Biol.
11:363–371. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Carpenter B, MacKay C, Alnabulsi A, et al:
The roles of heterogeneous nuclear ribonucleoproteins in tumour
development and progression. Biochim Biophys Acta. 1765:85–100.
2006.PubMed/NCBI
|
|
28.
|
Brockstedt E, Rickers A, Kostka S, et al:
Identification of apoptosis-associated proteins in a human Burkitt
lymphoma cell line. Cleavage of heterogeneous nuclear
ribonucleoprotein A1 by caspase 3. J Biol Chem. 273:28057–28064.
1998. View Article : Google Scholar
|
|
29.
|
Rahman-Roblick R, Johannes Roblick U,
Hellman U, et al: p53 targets identified by protein expression
profiling. Proc Natl Acad Sci USA. 104:5401–5406. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Koryllou A, Patrinou-Georgoula M, Troungos
C and Pletsa V: Cell death induced by N-methyl-N-nitrosourea, a
model SN1 methylating agent, in two lung cancer cell lines of human
origin. Apoptosis. 14:1121–1133. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Grover R, Sharathchandra A, Ponnuswamy A,
Khan D and Das S: Effect of mutations on the p53 IRES RNA
structure: Implications for de-regulation of the synthesis of p53
isoforms. RNA Biol. 8:132–142. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Hossain MN, Fuji M, Miki K, Endoh M and
Ayusawa D: Downregulation of hnRNP C1/C2 by siRNA sensitizes HeLa
cells to various stresses. Mol Cell Biochem. 296:151–157. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Ren F, Wu H, Lei Y, et al: Quantitative
proteomics identification of phosphoglycerate mutase 1 as a novel
therapeutic target in hepatocellular carcinoma. Mol Cancer.
9:812010. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Evans MJ, Saghatelian A, Sorensen EJ and
Cravatt BF: Target discovery in small-molecule cell-based screens
by in situ proteome reactivity profiling. Nat Biotechnol.
23:1303–1307. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Gao H, Yu B, Yan Y, et al: Correlation of
expression levels of ANXA2, PGAM1, and CALR with glioma grade and
prognosis. J Neurosurg. 118:846–853. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Jiang X, Sun Q, Li H, Li K and Ren X: The
role of phosphoglycerate mutase 1 in tumor aerobic glycolysis and
its potential therapeutic implications. Int J Cancer. Nov
28–2013.(Epub ahead of print). View Article : Google Scholar
|
|
37.
|
Chaneton B and Gottlieb E: PGAMgnam style:
a glycolytic switch controls biosynthesis. Cancer Cell. 22:565–566.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Tan JY, Huang X and Luo YL: PSMA7 inhibits
the tumorigenicity of A549 human lung adenocarcinoma cells. Mol
Cell Biochem. 366:131–137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Du H, Huang X, Wang S, Wu Y, Xu W and Li
M: PSMA7, a potential biomarker of diseases. Protein Pept Lett.
16:486–489. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Sakai A, Otani M, Miyamoto A, Yoshida H,
Furuya E and Tanigawa N: Identification of phosphorylated serine-15
and -82 residues of HSPB1 in 5-fluorouracil-resistant colorectal
cancer cells by proteomics. J Proteomics. 75:806–818. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Yung BY: Oncogenic role of
nucleophosmin/B23. Chang Gung Med J. 30:285–293. 2007.
|
|
42.
|
Wong JC, Hasan MR, Rahman M, et al:
Nucleophosmin 1, upregulated in adenomas and cancers of the colon,
inhibits p53-mediated cellular senescence. Int J Cancer.
133:1567–1577. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Lin M, Hu J, Liu T, Li J, Chen B and Chen
X: Knockdown of nucleophosmin by RNA interference reverses
multidrug resistance in resistant leukemic HL-60 cells.
Immunobiology. 218:1147–1154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Grisendi S, Mecucci C, Falini B and
Pandolfi PP: Nucleophosmin and cancer. Nat Rev Cancer. 6:493–505.
2006. View Article : Google Scholar
|
|
45.
|
Karhemo PR, Rivinoja A, Lundin J, et al:
An extensive tumor array analysis supports tumor suppressive role
for nucleophosmin in breast cancer. Am J Pathol. 179:1004–1014.
2011. View Article : Google Scholar : PubMed/NCBI
|
